Last reviewed · How we verify
Capastat Sulfate (CAPREOMYCIN)
Capreomycin, marketed by Epic Pharma LLC, is an established treatment for acute tuberculosis, with a key composition patent expiring in 2028. Its mechanism of inhibiting protein synthesis in Mycobacterium tuberculosis provides a targeted approach to combating the disease. The primary risk is competition from off-patent generics such as cycloserine and rifabutin, which may erode market share.
At a glance
| Generic name | CAPREOMYCIN |
|---|---|
| Sponsor | Epic Pharma Llc |
| Drug class | Antimycobacterial |
| Modality | Recombinant protein |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Acute tuberculosis
- Pulmonary tuberculosis
Common side effects
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
- Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
- Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capastat Sulfate CI brief — competitive landscape report
- Capastat Sulfate updates RSS · CI watch RSS
- Epic Pharma Llc portfolio CI